Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas

The Pediatric Infectious Disease Journal
Chonnamet TechasaensiriGeorge H McCracken

Abstract

The heptavalent pneumococcal conjugate vaccine (PCV7) has significantly reduced vaccine-type invasive pneumococcal disease (IPD) in children. An increasing percentage of IPD cases are now caused by nonvaccine serotypes. The purpose of our observational study was to define the epidemiology of pneumococcal disease in Dallas, TX children for 8 years after implementation of PCV7 immunization. Streptococcus pneumoniae isolates from normally sterile sites were collected at Children's Medical Center of Dallas from January 1, 1999 to December 31, 2008. Incidence of IPD was calculated using inpatient and emergency center admissions to Children's Medical Center of Dallas as the denominator. Isolates were serotyped and penicillin and cefotaxime susceptibilities were determined. Serotype 19A isolates were further characterized by multilocus sequence typing. Compared with the prevaccine period of 1999-2000, there was a significant reduction in the incidence of IPD from 2002 to 2008 (P < 0.05), although a significant increase in IPD incidence was observed from 2006 to 2008 (P = 0.038). The number of IPD cases caused by serotype 19A increased from 1999 to 2008 (P < 0.001). There were significant increases in penicillin and cefotaxime nonsusce...Continue Reading

References

Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W P HausdorffG R Siber
May 2, 2003·The New England Journal of Medicine·Cynthia G WhitneyUNKNOWN Active Bacterial Core Surveillance of the Emerging Infections Program Network
Jul 21, 2004·Briefings in Bioinformatics·Sudhir KumarMasatoshi Nei
Sep 10, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas R TalbotMarie R Griffin
Jun 7, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Carrie L ByingtonAndrew T Pavia
Nov 4, 2005·The Journal of Infectious Diseases·Rekha PaiUNKNOWN Active Bacterial Core Surveillance Team
Mar 7, 2006·Journal of Clinical Microbiology·Bernard BeallUNKNOWN Active Bacterial Core Surveillance Team
Apr 7, 2006·The New England Journal of Medicine·Moe H KyawUNKNOWN Active Bacterial Core Surveillance of the Emerging Infections Program Network
Feb 3, 2007·Journal of Clinical Microbiology·In Ho ParkMoon H Nahm
Apr 26, 2007·JAMA : the Journal of the American Medical Association·Timothy R Peters, Katherine A Poehling
Oct 18, 2007·JAMA : the Journal of the American Medical Association·Michael E Pichichero, Janet R Casey
May 22, 2008·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Robertino MeraRonald N Jones
Jan 16, 2009·The New England Journal of Medicine·Heather E HsuLee H Harrison

❮ Previous
Next ❯

Citations

Oct 28, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Naoko ChibaKimiko Ubukata
Nov 9, 2010·The Pediatric Infectious Disease Journal·Anne J BlaschkeKrow Ampofo
Feb 11, 2011·Current Infectious Disease Reports·Nida Hameed, Allan R Tunkel
Aug 10, 2012·Journal of Biological Dynamics·Maia Martcheva
Mar 20, 2012·The Pediatric Infectious Disease Journal·Susanna EspositoUNKNOWN Italian Pneumococcal CAP Group
Apr 16, 2014·The Pediatric Infectious Disease Journal·Whitney R HalgrimsonEric A F Simões
Jun 20, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ana Isabel Valdivielso MartínezDavid Moreno Pérez
Nov 3, 2011·The Annals of Pharmacotherapy·Allana J SucherBrandon J Sucher
Jun 19, 2012·Future Microbiology·Michael CunninghamItzhak Brook
Apr 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter R Paradiso
Apr 16, 2011·Lancet·Daniel M WeinbergerMarc Lipsitch
Sep 2, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John S BradleyUNKNOWN Pediatric Infectious Diseases Society and the Infectious Diseases Society of America
Nov 15, 2011·Expert Opinion on Biological Therapy·Robert W Frenck, Sylvia Yeh
Feb 15, 2012·Vaccine·Jae-Hoon SongBernard Fritzell
Aug 28, 2012·Diagnostic Microbiology and Infectious Disease·Susanna Hernandez-BouCarmen Muñoz-Almagro
Dec 1, 2012·Journal of the Pediatric Infectious Diseases Society·Derek J Williams, Samir S Shah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.